BR112015002574A8 - epítopo associado a tumor que estimula uma reação imune contra o tumor para uso na medicina; epítopo associado a tumor que estimula uma reação imune contra o tumor, e/ou um ácido nucleico; epítopo para uso; epítopo e/ou ácido nucleico para uso; epítopo; peptídeo; epítopo modificado que estimula uma reação imune de il-10 contra auto-antígenos para uso na medicina; método para prever a sobrevivência em câncer colorretal; e método para prever a sobrevivência em câncer de ovário. - Google Patents
epítopo associado a tumor que estimula uma reação imune contra o tumor para uso na medicina; epítopo associado a tumor que estimula uma reação imune contra o tumor, e/ou um ácido nucleico; epítopo para uso; epítopo e/ou ácido nucleico para uso; epítopo; peptídeo; epítopo modificado que estimula uma reação imune de il-10 contra auto-antígenos para uso na medicina; método para prever a sobrevivência em câncer colorretal; e método para prever a sobrevivência em câncer de ovário.Info
- Publication number
- BR112015002574A8 BR112015002574A8 BR112015002574A BR112015002574A BR112015002574A8 BR 112015002574 A8 BR112015002574 A8 BR 112015002574A8 BR 112015002574 A BR112015002574 A BR 112015002574A BR 112015002574 A BR112015002574 A BR 112015002574A BR 112015002574 A8 BR112015002574 A8 BR 112015002574A8
- Authority
- BR
- Brazil
- Prior art keywords
- epitope
- tumor
- stimulates
- immune reaction
- medicine
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 4
- 230000008105 immune reaction Effects 0.000 title 3
- 239000003814 drug Substances 0.000 title 2
- 238000000034 method Methods 0.000 title 2
- 108020004707 nucleic acids Proteins 0.000 title 2
- 150000007523 nucleic acids Chemical class 0.000 title 2
- 102000039446 nucleic acids Human genes 0.000 title 2
- 230000004083 survival effect Effects 0.000 title 2
- 206010009944 Colon cancer Diseases 0.000 title 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 title 1
- 206010033128 Ovarian cancer Diseases 0.000 title 1
- 206010061535 Ovarian neoplasm Diseases 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001176—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/18—Post-translational modifications [PTMs] in chemical analysis of biological material citrullination
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1214007.5A GB201214007D0 (en) | 2012-08-07 | 2012-08-07 | Anti-tumour immune responses to modified self-epitopes |
PCT/GB2013/052109 WO2014023957A2 (en) | 2012-08-07 | 2013-08-07 | Anti-tumour response to modified self-epitopes |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015002574A2 BR112015002574A2 (pt) | 2017-11-07 |
BR112015002574A8 true BR112015002574A8 (pt) | 2018-01-23 |
Family
ID=46934958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015002574A BR112015002574A8 (pt) | 2012-08-07 | 2013-08-07 | epítopo associado a tumor que estimula uma reação imune contra o tumor para uso na medicina; epítopo associado a tumor que estimula uma reação imune contra o tumor, e/ou um ácido nucleico; epítopo para uso; epítopo e/ou ácido nucleico para uso; epítopo; peptídeo; epítopo modificado que estimula uma reação imune de il-10 contra auto-antígenos para uso na medicina; método para prever a sobrevivência em câncer colorretal; e método para prever a sobrevivência em câncer de ovário. |
Country Status (18)
Country | Link |
---|---|
US (4) | US10233220B2 (pt) |
EP (3) | EP3301447B1 (pt) |
JP (2) | JP6490581B2 (pt) |
KR (1) | KR102203096B1 (pt) |
CN (2) | CN107043414A (pt) |
AU (1) | AU2013301341B2 (pt) |
BR (1) | BR112015002574A8 (pt) |
CA (1) | CA2874515A1 (pt) |
DK (3) | DK3301447T3 (pt) |
ES (3) | ES2833962T3 (pt) |
GB (1) | GB201214007D0 (pt) |
HK (1) | HK1206427A1 (pt) |
IN (1) | IN2014DN10629A (pt) |
PL (2) | PL3301447T3 (pt) |
PT (3) | PT3287787T (pt) |
SG (2) | SG11201407804RA (pt) |
WO (1) | WO2014023957A2 (pt) |
ZA (1) | ZA201409095B (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3061462B1 (en) | 2007-07-02 | 2019-02-27 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
GB201214007D0 (en) | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
WO2015169602A1 (en) | 2014-05-05 | 2015-11-12 | Noviosmart | Method for the serological diagnosis of rheumatoid arthritis. |
CN104360070B (zh) * | 2014-11-28 | 2017-02-22 | 山东新创生物科技有限公司 | 肽基精氨酸脱亚胺酶2在制备肿瘤临床血液诊断试剂中的应用 |
KR102193635B1 (ko) | 2015-01-09 | 2020-12-21 | 이투빅스 코포레이션 | 복합 면역요법을 위한 방법 및 조성물 |
WO2016172249A1 (en) | 2015-04-20 | 2016-10-27 | Etubics Corporation | Methods and compositions for combination immunotherapy |
US10568948B2 (en) | 2015-05-13 | 2020-02-25 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
GB201512703D0 (en) | 2015-07-20 | 2015-08-26 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
SG10202111399YA (en) * | 2015-12-22 | 2021-11-29 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
GB201522667D0 (en) * | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
WO2018046648A1 (en) * | 2016-09-08 | 2018-03-15 | Katholieke Universiteit Leuven | Citrullinated peptides for diagnosis or treatment of diabetes |
KR102184377B1 (ko) * | 2018-02-19 | 2020-11-30 | 고려대학교 산학협력단 | 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도 |
MA52363A (fr) | 2018-04-26 | 2021-03-03 | Agenus Inc | Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation |
GB201815041D0 (en) | 2018-09-14 | 2018-10-31 | Scancell Ltd | Epitopes |
GB202005779D0 (en) | 2020-04-21 | 2020-06-03 | Scancell Ltd | Anti-tumour immune responses |
CN112194719A (zh) * | 2020-09-01 | 2021-01-08 | 中日友好医院(中日友好临床医学研究所) | Crt抗原和mage-a1抗原的制备及其应用 |
GB202018395D0 (en) | 2020-11-23 | 2021-01-06 | Scancell Ltd | Immunotherapy |
CN114404570B (zh) * | 2022-01-20 | 2023-05-30 | 中国药科大学 | 一种新型抗肿瘤转移多肽及其应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002051785A (ja) * | 2000-08-09 | 2002-02-19 | Hagiwara Yoshihide | 抗癌ヒトモノクローナル抗体CLN−IgGによって認識される抗原エピトープのアミノ酸配列およびそれをコードするDNAヌクレオチド配列 |
AU2002210407A1 (en) * | 2000-10-27 | 2002-05-06 | Pharmexa A/S | Therapeutic vaccine formulations containing chitosan |
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
US20030138425A1 (en) * | 2001-09-21 | 2003-07-24 | Mather Jennie Powell | Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof |
EP1461001A4 (en) * | 2002-01-03 | 2010-03-31 | Scripps Research Inst | EPITOPE ASSOCIATED WITH CANCER |
US20040013649A1 (en) * | 2002-05-10 | 2004-01-22 | Inex Pharmaceuticals Corporation | Cancer vaccines and methods of using the same |
EP2426139B1 (en) | 2002-08-27 | 2014-10-01 | Biokine Therapeutics Ltd. | CXCR4 antagonist and use thereof |
DE60322559D1 (de) * | 2002-10-02 | 2008-09-11 | Hoffmann La Roche | Neue, mhc klasse ii assoziierte peptide |
US7670604B2 (en) * | 2002-12-13 | 2010-03-02 | Aurelium Biopharma, Inc. | Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
DE10313819A1 (de) * | 2003-03-24 | 2004-10-07 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
EP1695089A1 (en) | 2003-12-15 | 2006-08-30 | Aurelium Biopharma Inc. | Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
EP1890724A2 (en) * | 2005-05-13 | 2008-02-27 | Oxxon Therapeutics Limited | Compositions for inducing an immune response |
DE102005029845B4 (de) * | 2005-06-27 | 2017-03-23 | Orgentec Diagnostika Gmbh | Verfahren zur Diagnose von rheumatischen Erkrankungen |
CN1712964A (zh) * | 2005-07-18 | 2005-12-28 | 山东省医药生物技术研究中心 | 类风湿性关节炎特异性抗原性标志物及其应用 |
US20070248628A1 (en) * | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
CA2638866C (en) * | 2006-02-17 | 2015-11-10 | Indiana University Research And Technology Corporation | Peptide based inhibition of capcna protein-protein interactions in cancer |
WO2007098093A2 (en) * | 2006-02-17 | 2007-08-30 | Five Prime Therapeutics, Inc. | Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma |
WO2007127160A2 (en) * | 2006-04-24 | 2007-11-08 | Shantha West, Inc. | Agrm2 antigen |
DE602006013809D1 (de) * | 2006-07-24 | 2010-06-02 | Facultad De Medicina Universid | Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden |
WO2009015841A1 (en) * | 2007-07-27 | 2009-02-05 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
CA2712080A1 (en) * | 2008-02-08 | 2009-08-13 | The Scripps Research Institute | Breaking immunological tolerance with a genetically encoded unnatural amino acid |
CA2757444A1 (en) * | 2009-03-30 | 2010-10-14 | Prometheus Laboratories Inc. | Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis |
ES2788863T3 (es) * | 2010-05-14 | 2020-10-23 | Massachusetts Gen Hospital | Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores |
WO2012095849A1 (en) | 2011-01-10 | 2012-07-19 | Biokine Therapeutics Ltd. | Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma |
EP2667888A4 (en) | 2011-01-28 | 2015-11-11 | Univ Oregon Health & Science | LIGMPHES OF RECOMBINANT T LYMPHOCYTES AND ANTIBODIES BINDING TO LYMPHOCYTES B FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
ES2777502T3 (es) | 2011-04-05 | 2020-08-05 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung Ev | Novedosos péptidos y su uso en diagnóstico y tratamiento |
US20120295292A1 (en) * | 2011-05-19 | 2012-11-22 | University Of South Carolina | Detecting Protein Arginine Deiminase (PAD) Activity in Human Tissues and Sera |
US20130274125A1 (en) * | 2012-04-16 | 2013-10-17 | Bio-Rad Laboratories Inc. | Multiplex immunoassay for rheumatoid arthritis and other autoimmune diseases |
GB201214007D0 (en) | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
-
2012
- 2012-08-07 GB GBGB1214007.5A patent/GB201214007D0/en not_active Ceased
-
2013
- 2013-08-07 EP EP17194252.7A patent/EP3301447B1/en active Active
- 2013-08-07 EP EP17194251.9A patent/EP3287787B1/en active Active
- 2013-08-07 DK DK17194252.7T patent/DK3301447T3/da active
- 2013-08-07 IN IN10629DEN2014 patent/IN2014DN10629A/en unknown
- 2013-08-07 EP EP13750368.6A patent/EP2883054B1/en active Active
- 2013-08-07 PL PL17194252T patent/PL3301447T3/pl unknown
- 2013-08-07 ES ES17194251T patent/ES2833962T3/es active Active
- 2013-08-07 DK DK13750368.6T patent/DK2883054T3/en active
- 2013-08-07 SG SG11201407804RA patent/SG11201407804RA/en unknown
- 2013-08-07 KR KR1020157004947A patent/KR102203096B1/ko active IP Right Grant
- 2013-08-07 ES ES17194252T patent/ES2843777T3/es active Active
- 2013-08-07 PT PT171942519T patent/PT3287787T/pt unknown
- 2013-08-07 CA CA2874515A patent/CA2874515A1/en active Pending
- 2013-08-07 JP JP2015525944A patent/JP6490581B2/ja active Active
- 2013-08-07 WO PCT/GB2013/052109 patent/WO2014023957A2/en active Application Filing
- 2013-08-07 PT PT171942527T patent/PT3301447T/pt unknown
- 2013-08-07 CN CN201611090520.1A patent/CN107043414A/zh active Pending
- 2013-08-07 AU AU2013301341A patent/AU2013301341B2/en active Active
- 2013-08-07 PT PT13750368T patent/PT2883054T/pt unknown
- 2013-08-07 DK DK17194251.9T patent/DK3287787T3/da active
- 2013-08-07 SG SG10201701001VA patent/SG10201701001VA/en unknown
- 2013-08-07 CN CN201380041701.3A patent/CN104823054B/zh active Active
- 2013-08-07 PL PL17194251T patent/PL3287787T3/pl unknown
- 2013-08-07 BR BR112015002574A patent/BR112015002574A8/pt not_active Application Discontinuation
- 2013-08-07 ES ES13750368T patent/ES2681973T3/es active Active
-
2014
- 2014-12-10 ZA ZA2014/09095A patent/ZA201409095B/en unknown
-
2015
- 2015-02-05 US US14/614,964 patent/US10233220B2/en active Active
- 2015-07-22 HK HK15106996.4A patent/HK1206427A1/xx unknown
-
2018
- 2018-06-13 US US16/007,944 patent/US20180346537A1/en not_active Abandoned
- 2018-06-26 JP JP2018120859A patent/JP2018197236A/ja active Pending
-
2020
- 2020-12-22 US US17/131,532 patent/US20210198334A1/en not_active Abandoned
-
2022
- 2022-08-01 US US17/878,533 patent/US20230192790A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015002574A8 (pt) | epítopo associado a tumor que estimula uma reação imune contra o tumor para uso na medicina; epítopo associado a tumor que estimula uma reação imune contra o tumor, e/ou um ácido nucleico; epítopo para uso; epítopo e/ou ácido nucleico para uso; epítopo; peptídeo; epítopo modificado que estimula uma reação imune de il-10 contra auto-antígenos para uso na medicina; método para prever a sobrevivência em câncer colorretal; e método para prever a sobrevivência em câncer de ovário. | |
IL270886A (en) | Systems and methods for identifying responders and non-responders to immune checkpoint inhibitor therapy | |
CY1121723T1 (el) | Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων | |
HK1247213A1 (zh) | Pd-l1抗體、其抗原結合片段及其醫藥用途 | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
CL2016002004A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
BR112017025564B8 (pt) | Anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
BR112016014284A2 (pt) | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo | |
EP3265113A4 (en) | ANTI-LRB ANTIBODIES AND THEIR USE FOR THE DETECTION AND TREATMENT OF CANCER | |
BR112017011326A2 (pt) | anticorpo, ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo, imunoconjugado, composição farmacêutica, usos do anticorpo, métodos para tratar ou retardar a progressão de distúrbio proliferativo celular e para intensificar a função imune | |
EP3074035A4 (en) | Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy | |
MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
EP3213056A4 (en) | Methods for the rapid preparation of labeled glycosylamines and for the analysis of glycosylated biomolecules producing the same | |
AR090549A1 (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
CL2011002784A1 (es) | Anticuerpo anti-egfl7; acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion que lo comprende, y su uso para tratar un tumor, cancer o un trastorno proliferativo. | |
WO2013116778A3 (en) | Adenoviruses expressing heterologous tumor-associated antigens | |
BR112013011705A2 (pt) | antígenos consensuais de próstata, molécula de ácido nucleico que os codificam e vacina e usos que os compreendem | |
EP2970443A4 (en) | Cancer treatment using antibodies that bind cell surface grp78 | |
EP3144857A4 (en) | Two-dimensional code, two-dimensional-code analysis system, and two-dimensional-code generation system | |
EP4282881A3 (en) | Antibodies against csf-1r | |
EP3144856A4 (en) | Two-dimensional code, and two-dimensional-code analysis system | |
PH12016500753B1 (en) | Antibodies specific to fcrn | |
CL2015001230A1 (es) | Método de selección de proteínas ligantes de antígeno her3 humano y her4 humano; proteína ligante; anticuerpo ligante de her3 y her4; ácido nucleico que lo codifica; célula huésped; método de producción; formulación farmacéutica que lo comprende; uso para tratar el cáncer; y epítopos. | |
BR112015003032A8 (pt) | anticorpos isolados,ácidos nucleico isolados,célula hospedeira,método de produzir um anticorpo,imunoconjugado,formulação famacêutica,uso do anticorpo e método de tratamento de um indivíduo. | |
EP3183945A4 (en) | Particle therapy systems, devices, and methods for beam transportation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |